Remote Sensing - based precision agriculture tool for the sugar industry

This project aimed to develop remote sensing applications that were both relevant and of commercial benefit to the Australian sugar industry and therefore adoptable. Such applications included the in season mapping of crop vigour so as to guide future management strategies, the identification of specific abiotic and biotic cropping constraints, and the conversion of GNDVI variability maps into yield at the block, farm and regional level. In order to achieve these applications the project team reviewed an array of remote sensing platforms, timing of imagery capture, software and analysis protocols; as well as distribution formats of derived imagery products, to a range of end users. The project developed strong collaborative linkages with all levels of the industry including mills, productivity services, agronomists, growers and researchers and increased its initial coverage from three individual farms in Bundaberg, Burdekin and the Herbert, coinciding with project CSE022, to include over 33,000 crops grown across 6 growing regions (Mulgrave, Herbert, Burdekin, Bundaberg, ISIS and Condong) during the 2011/2012 season

Remote Sensing - based precision agriculture tool for the sugar industry

This project aimed to develop remote sensing applications that were both relevant and of commercial benefit to the Australian sugar industry and therefore adoptable. Such applications included the in season mapping of crop vigour so as to guide future management strategies, the identification of specific abiotic and biotic cropping constraints, and the conversion of GNDVI variability maps into yield at the block, farm and regional level. In order to achieve these applications the project team reviewed an array of remote sensing platforms, timing of imagery capture, software and analysis protocols; as well as distribution formats of derived imagery products, to a range of end users. The project developed strong collaborative linkages with all levels of the industry including mills, productivity services, agronomists, growers and researchers and increased its initial coverage from three individual farms in Bundaberg, Burdekin and the Herbert, coinciding with project CSE022, to include over 33,000 crops grown across 6 growing regions (Mulgrave, Herbert, Burdekin, Bundaberg, ISIS and Condong) during the 2011/2012 season

Acquisition of a Distributed Computation and Immersive Visualization Environment for Complex Systems - Scientific Applications on Arrays of Multiprocessors (SCAAMP)

NSF Award ID: CDA-9601632 9/15/1996-8/31/199

HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer

BACKGROUND: Oestrogen receptor positive/ human epidermal growth factor receptor positive (ER+/HER2+) breast cancers (BCs) are less responsive to endocrine therapy than ER+/HER2- tumours. Mechanisms underpinning the differential behaviour of ER+HER2+ tumours are poorly characterised. Our aim was to identify biomarkers of response to 2 weeks’ presurgical AI treatment in ER+/HER2+ BCs. METHODS: All available ER+/HER2+ BC baseline tumours (n=342) in the POETIC trial were gene expression profiled using BC360™ (NanoString) covering intrinsic subtypes and 46 key biological signatures. Early response to AI was assessed by changes in Ki67 expression and residual Ki67 at 2 weeks (Ki672wk). Time-To-Recurrence (TTR) was estimated using Kaplan-Meier methods and Cox models adjusted for standard clinicopathological variables. New molecular subgroups (MS) were identified using consensus clustering. FINDINGS: HER2-enriched (HER2-E) subtype BCs (44.7% of the total) showed poorer Ki67 response and higher Ki672wk (p<0.0001) than non-HER2-E BCs. High expression of ERBB2 expression, homologous recombination deficiency (HRD) and TP53 mutational score were associated with poor response and immune-related signatures with High Ki672wk. Five new MS that were associated with differential response to AI were identified. HER2-E had significantly poorer TTR compared to Luminal BCs (HR 2.55, 95% CI 1.14–5.69; p=0.0222). The new MS were independent predictors of TTR, adding significant value beyond intrinsic subtypes. INTERPRETATION: Our results show HER2-E as a standardised biomarker associated with poor response to AI and worse outcome in ER+/HER2+. HRD, TP53 mutational score and immune-tumour tolerance are predictive biomarkers for poor response to AI. Lastly, novel MS identify additional non-HER2-E tumours not responding to AI with an increased risk of relapse

Breast cancer management pathways during the COVID-19 pandemic: outcomes from the UK ‘Alert Level 4’ phase of the B-MaP-C study

Abstract: Background: The B-MaP-C study aimed to determine alterations to breast cancer (BC) management during the peak transmission period of the UK COVID-19 pandemic and the potential impact of these treatment decisions. Methods: This was a national cohort study of patients with early BC undergoing multidisciplinary team (MDT)-guided treatment recommendations during the pandemic, designated ‘standard’ or ‘COVID-altered’, in the preoperative, operative and post-operative setting. Findings: Of 3776 patients (from 64 UK units) in the study, 2246 (59%) had ‘COVID-altered’ management. ‘Bridging’ endocrine therapy was used (n = 951) where theatre capacity was reduced. There was increasing access to COVID-19 low-risk theatres during the study period (59%). In line with national guidance, immediate breast reconstruction was avoided (n = 299). Where adjuvant chemotherapy was omitted (n = 81), the median benefit was only 3% (IQR 2–9%) using ‘NHS Predict’. There was the rapid adoption of new evidence-based hypofractionated radiotherapy (n = 781, from 46 units). Only 14 patients (1%) tested positive for SARS-CoV-2 during their treatment journey. Conclusions: The majority of ‘COVID-altered’ management decisions were largely in line with pre-COVID evidence-based guidelines, implying that breast cancer survival outcomes are unlikely to be negatively impacted by the pandemic. However, in this study, the potential impact of delays to BC presentation or diagnosis remains unknown

Bridging pre-surgical endocrine therapy for breast cancer during the COVID-19 pandemic: outcomes from the B-MaP-C study

Purpose: The B-MaP-C study investigated changes to breast cancer care that were necessitated by the COVID-19 pandemic. Here we present a follow-up analysis of those patients commenced on bridging endocrine therapy (BrET), whilst they were awaiting surgery due to reprioritisation of resources. Methods: This multicentre, multinational cohort study recruited 6045 patients from the UK, Spain and Portugal during the peak pandemic period (Feb–July 2020). Patients on BrET were followed up to investigate the duration of, and response to, BrET. This included changes in tumour size to reflect downstaging potential, and changes in cellular proliferation (Ki67), as a marker of prognosis. Results: 1094 patients were prescribed BrET, over a median period of 53 days (IQR 32–81 days). The majority of patients (95.6%) had strong ER expression (Allred score 7–8/8). Very few patients required expedited surgery, due to lack of response (1.2%) or due to lack of tolerance/compliance (0.8%). There were small reductions in median tumour size after 3 months’ treatment duration; median of 4 mm [IQR − 20, 4]. In a small subset of patients ( n = 47), a drop in cellular proliferation (Ki67) occurred in 26 patients (55%), from high (Ki67 ≥ 10%) to low (&lt; 10%), with at least one month’s duration of BrET. Discussion: This study describes real-world usage of pre-operative endocrine therapy as necessitated by the pandemic. BrET was found to be tolerable and safe. The data support short-term (≤ 3 months) usage of pre-operative endocrine therapy. Longer-term use should be investigated in future trials

Lessons learned from winegrape producers in Australia about effective collaboration during on-farm experimentation

We report the experiences of vineyard managers and viticultural consultants during collaborative On-Farm Experimentation (OFE) designed to support business decisions. Previous research involving winegrape producers across Australia revealed constraints to farmers’ experiments even though these were valued for their potential to answer business-specific questions. In the study reported here, producers involved in four collaborative trials perceived a feasible approach that provided them with insights upon which they could act. The active engagement of researchers and consultants fostered a shared understanding of the capacities, capabilities, and resources needed for this approach while catalyzing further investigation and/or in-business conversations that would not have occurred otherwise. We explored the value proposition for collaborative OFE involving farmers, consultants, and institutional researchers aimed at generating rigorous results from trials aligned with the farming context